Why Is Cancer Player Candel Therapeutics Stock Trading Higher Today?

Candel Therapeutics Inc (NASDAQ: CADL) released initial interim survival and immunological biomarker data from the ongoing phase 2 trial of CAN-2409 plus valacyclovir (prodrug) together with standard of care (SoC) chemoradiation followed by resection for borderline resectable pancreatic ductal adenocarcinoma (PDAC)

Data were presented at the 2023 Society for Immunotherapy Annual Meeting.

An estimated survival rate of 71.4% at both 24 and 36 months was observed in patients who received the CAN-2409 regimen together with SoC chemoradiation before surgery, ...

Full story available on

Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.

Disclaimer Press Release Banner